anastrozole has been researched along with Carcinoma, Lobular in 20 studies
Carcinoma, Lobular: A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.
| Excerpt | Relevance | Reference |
|---|---|---|
| "27 compared 5 years of adjuvant anastrozole or exemestane in postmenopausal patients with hormone receptor positive early breast cancer." | 9.27 | Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. ( Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G, 2018) |
| "Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women." | 9.19 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G, 2014) |
| " We report an unusual case of urticarial vasculitis following the aromatase inhibitor anastrozole that localised to the unilateral trunk and mastectomy scar, and review the literature on the cutaneous adverse effects of hormonal therapy for breast cancer." | 8.90 | Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. ( Bock, VL; Friedlander, M; Kossard, S; Waring, D; Wood, GK, 2014) |
| "A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455)." | 7.83 | Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. ( Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K, 2016) |
| "27 compared 5 years of adjuvant anastrozole or exemestane in postmenopausal patients with hormone receptor positive early breast cancer." | 5.27 | Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. ( Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G, 2018) |
| "Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women." | 5.19 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. ( Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G, 2014) |
| " We report an unusual case of urticarial vasculitis following the aromatase inhibitor anastrozole that localised to the unilateral trunk and mastectomy scar, and review the literature on the cutaneous adverse effects of hormonal therapy for breast cancer." | 4.90 | Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. ( Bock, VL; Friedlander, M; Kossard, S; Waring, D; Wood, GK, 2014) |
| "A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455)." | 3.83 | Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. ( Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K, 2016) |
| "Aromatase inhibitors (AIs) are more effective than tamoxifen as neoadjuvant endocrine therapy (NET) for hormone receptor (HR)-positive breast cancer." | 3.80 | Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. ( Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M, 2014) |
| "We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil." | 3.73 | t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006) |
| "Although approximately 60 % of breast cancers in premenopausal women are HR positive, the role of neoadjuvant ET in this population is not well defined." | 1.42 | Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. ( Barbie, TU; Ma, C; Margenthaler, JA, 2015) |
| "Breast cancer is the most frequent primary site of metastasis to the uterine corpus, with invasive lobular carcinoma more likely to spread to gynecologic organs than invasive ductal carcinoma." | 1.42 | Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report. ( Akagi, K; Hayasaka, A; Igeta, S; Ishigaki, N; Iwahashi, H; Kudo, T; Makino, H; Matsuura, R; Sakurada, J; Shima, T; Suzuki, H; Toyoshima, M; Yoshinaga, K, 2015) |
| "The percentage of women≥75 years with breast cancer receiving PET in the south of the Netherlands decreased from 23% in the period 1988-1992 to 12% in 1997-2000, and increased to 29% in 2005-2008." | 1.38 | Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. ( Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K, 2012) |
| "Rectal metastases from breast carcinomas are very rare." | 1.36 | Rectal metastasis from lobular carcinoma of the breast: a case report. ( Balja, MP; Knezević, F; Sitić, S; Stanec, M; Supić, DK; Vrdoljak, DV, 2010) |
| "Lobular carcinoma is the most common type of breast cancer that metastasizes to the uterus." | 1.35 | Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy. ( Barisik, NO; Bilici, A; Gumus, M; Salepci, T; Salman, T; Seker, M; Ustaalioglu, BB; Yaylaci, M, 2009) |
| "This is the first report of breast carcinoma metastatic to the endometrium in a patient on adjuvant anastrozole therapy." | 1.33 | Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy. ( Bolat, F; Erkanli, S; Haberal, A; Kayaselcuk, F; Kuscu, E; Sakalli, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strasser-Weippl, K | 1 |
| Sudan, G | 1 |
| Ramjeesingh, R | 1 |
| Shepherd, LE | 1 |
| O'Shaughnessy, J | 1 |
| Parulekar, WR | 1 |
| Liedke, PER | 1 |
| Chen, BE | 1 |
| Goss, PE | 1 |
| Sathiamoorthi, S | 1 |
| Ruddy, KJ | 1 |
| Bakri, SJ | 1 |
| Cameron, DA | 1 |
| Cuzick, J | 1 |
| Sestak, I | 1 |
| Forbes, JF | 1 |
| Dowsett, M | 2 |
| Knox, J | 1 |
| Cawthorn, S | 1 |
| Saunders, C | 1 |
| Roche, N | 1 |
| Mansel, RE | 1 |
| von Minckwitz, G | 1 |
| Bonanni, B | 1 |
| Palva, T | 1 |
| Howell, A | 1 |
| Grassadonia, A | 1 |
| Di Nicola, M | 1 |
| Grossi, S | 1 |
| Noccioli, P | 1 |
| Tavoletta, S | 1 |
| Politi, R | 1 |
| Angelucci, D | 1 |
| Marinelli, C | 1 |
| Zilli, M | 1 |
| Ausili Cefaro, G | 1 |
| Tinari, N | 1 |
| De Tursi, M | 1 |
| Iezzi, L | 1 |
| Cioffi, P | 1 |
| Iacobelli, S | 1 |
| Natoli, C | 1 |
| Cianchetti, E | 1 |
| Bock, VL | 1 |
| Friedlander, M | 1 |
| Waring, D | 1 |
| Kossard, S | 1 |
| Wood, GK | 1 |
| Barbie, TU | 1 |
| Ma, C | 1 |
| Margenthaler, JA | 1 |
| Toyoshima, M | 1 |
| Iwahashi, H | 1 |
| Shima, T | 1 |
| Hayasaka, A | 1 |
| Kudo, T | 1 |
| Makino, H | 1 |
| Igeta, S | 1 |
| Matsuura, R | 1 |
| Ishigaki, N | 1 |
| Akagi, K | 1 |
| Sakurada, J | 1 |
| Suzuki, H | 1 |
| Yoshinaga, K | 1 |
| Egawa, C | 1 |
| Hirokaga, K | 1 |
| Takao, S | 1 |
| Yamagami, K | 1 |
| Miyashita, M | 1 |
| Baba, M | 1 |
| Ichii, S | 1 |
| Konishi, M | 1 |
| Kikawa, Y | 1 |
| Minohata, J | 1 |
| Okuno, T | 1 |
| Miyauchi, K | 1 |
| Wakita, K | 1 |
| Suwa, H | 1 |
| Hashimoto, T | 1 |
| Nishino, M | 1 |
| Matsumoto, T | 1 |
| Hidaka, T | 1 |
| Konishi, Y | 1 |
| Sakoda, Y | 1 |
| Miya, A | 1 |
| Mitsunobu, M | 1 |
| Nishikawa, H | 1 |
| Kono, S | 1 |
| Kokufu, I | 1 |
| Sakita, I | 1 |
| Kitatsuji, K | 1 |
| Oh, K | 1 |
| Miyoshi, Y | 1 |
| Sansone, P | 1 |
| Ceccarelli, C | 1 |
| Berishaj, M | 1 |
| Chang, Q | 1 |
| Rajasekhar, VK | 1 |
| Perna, F | 1 |
| Bowman, RL | 1 |
| Vidone, M | 1 |
| Daly, L | 1 |
| Nnoli, J | 1 |
| Santini, D | 1 |
| Taffurelli, M | 1 |
| Shih, NN | 1 |
| Feldman, M | 1 |
| Mao, JJ | 1 |
| Colameco, C | 1 |
| Chen, J | 1 |
| DeMichele, A | 1 |
| Fabbri, N | 1 |
| Healey, JH | 1 |
| Cricca, M | 1 |
| Gasparre, G | 1 |
| Lyden, D | 1 |
| Bonafé, M | 1 |
| Bromberg, J | 1 |
| Lerebours, F | 1 |
| Rivera, S | 1 |
| Mouret-Reynier, MA | 1 |
| Alran, S | 1 |
| Venat-Bouvet, L | 1 |
| Kerbrat, P | 1 |
| Salmon, R | 1 |
| Becette, V | 1 |
| Bourgier, C | 1 |
| Cherel, P | 1 |
| Boussion, V | 1 |
| Balleyguier, C | 1 |
| Thibault, F | 1 |
| Lavau-Denes, S | 1 |
| Nabholz, JM | 1 |
| Sigal, B | 1 |
| Trassard, M | 1 |
| Mathieu, MC | 1 |
| Martin, AL | 1 |
| Lemonnier, J | 1 |
| Mouret-Fourme, E | 1 |
| Ustaalioglu, BB | 1 |
| Bilici, A | 1 |
| Seker, M | 1 |
| Salman, T | 1 |
| Gumus, M | 1 |
| Barisik, NO | 1 |
| Salepci, T | 1 |
| Yaylaci, M | 1 |
| Balja, MP | 1 |
| Vrdoljak, DV | 1 |
| Stanec, M | 1 |
| Sitić, S | 1 |
| Supić, DK | 1 |
| Knezević, F | 1 |
| Prowell, TM | 1 |
| Blackford, AL | 1 |
| Byrne, C | 1 |
| Khouri, NF | 1 |
| Folkerd, E | 1 |
| Tarpinian, KS | 1 |
| Powers, PP | 1 |
| Wright, LA | 1 |
| Donehower, MG | 1 |
| Jeter, SC | 1 |
| Armstrong, DK | 1 |
| Emens, LA | 1 |
| Fetting, JH | 1 |
| Wolff, AC | 1 |
| Garrett-Mayer, E | 1 |
| Skaar, TC | 1 |
| Davidson, NE | 1 |
| Stearns, V | 1 |
| Wink, CJ | 1 |
| Woensdregt, K | 1 |
| Nieuwenhuijzen, GA | 1 |
| van der Sangen, MJ | 1 |
| Hutschemaekers, S | 1 |
| Roukema, JA | 1 |
| Tjan-Heijnen, VC | 1 |
| Voogd, AC | 1 |
| Erkanli, S | 1 |
| Kayaselcuk, F | 1 |
| Kuscu, E | 1 |
| Bolat, F | 1 |
| Sakalli, H | 1 |
| Haberal, A | 1 |
| Zapata, E | 1 |
| Zubiaurre, L | 1 |
| Bujanda, L | 1 |
| Piérola, A | 1 |
| Goodwin, GM | 1 |
| Resnik, KS | 1 |
| DiLeonardo, M | 1 |
| Gibbons, G | 1 |
| Sahin, FI | 1 |
| Yilmaz, Z | 1 |
| Karakuş, S | 1 |
| Boğa, S | 1 |
| Akçali, Z | 1 |
| DemIrhan, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer[NCT00066573] | Phase 3 | 7,576 participants (Actual) | Interventional | 2003-06-06 | Completed | ||
| International Breast Cancer Intervention Study[NCT00078832] | Phase 3 | 3,864 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Effects of Progressive Relaxation Training on Artralgia, Quality of Life and Emotional Status in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy[NCT04163692] | 44 participants (Actual) | Interventional | 2019-10-25 | Completed | |||
| A Randomized Multicenter Phase II Study Identifying Hormone Sensitivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women.[NCT00629616] | Phase 2 | 116 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy[NCT00244959] | Phase 2 | 54 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures. (NCT00066573)
Timeframe: 8 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Exemestane | 358 |
| Anastrozole | 354 |
Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver. (NCT00066573)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Exemestane | 157 |
| Anastrozole | 164 |
Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. (NCT00066573)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Exemestane | 88 |
| Anastrozole | 89 |
Overall survival is defined as the time from randomization to the time of death from any cause. (NCT00066573)
Timeframe: 5 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Exemestane | 92 |
| Anastrozole | 92 |
1 review available for anastrozole and Carcinoma, Lobular
| Article | Year |
|---|---|
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Chemothera | 2014 |
3 trials available for anastrozole and Carcinoma, Lobular
| Article | Year |
|---|---|
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms | 2018 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2014 |
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2016 |
16 other studies available for anastrozole and Carcinoma, Lobular
| Article | Year |
|---|---|
Association of Uveitis and Macular Edema With Anastrozole Therapy.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Female; Fluorescein A | 2018 |
Breast cancer chemoprevention: little progress in practice?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2014 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobula | 2015 |
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duct | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; | 2016 |
Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Diagnosis, Diffe | 2009 |
Rectal metastasis from lobular carcinoma of the breast: a case report.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobula | 2010 |
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcin | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2012 |
Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2006 |
Anastrozole-induced hepatotoxicity.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2006 |
Aromatase inhibitors and bipolar mood disorder: a case report.
Topics: Aggression; Anastrozole; Aromatase Inhibitors; Bipolar Disorder; Breast Neoplasms; Carcinoma, Lobula | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2006 |